Ralfinamide

Last updated
Ralfinamide
Ralfinamide.svg
Clinical data
ATC code
  • None
Identifiers
  • N2-{4-[(2-Fluorobenzyl)oxy]benzyl}-L-alaninamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.120.272 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C17H19FN2O2
Molar mass 302.349 g·mol−1
3D model (JSmol)
  • C[C@@H](C(=O)N)NCc1ccc(cc1)OCc2ccccc2F
  • InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-6-8-15(9-7-13)22-11-14-4-2-3-5-16(14)18/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
  • Key:BHJIBOFHEFDSAU-LBPRGKRZSA-N

Ralfinamide (INN; development codes NW-1029, FCE-26742A, and PNU-0154339E) [1] is a multimodal drug which is under investigation by Newron Pharmaceuticals for the treatment of neuropathic pain and other pain conditions such as post-operative dental pain. [2] [3] [4] [5]

Contents

It has a relatively complex pharmacology, acting as a mixed voltage-gated sodium channel blocker (including Nav1.7), [2] [3] N-type calcium channel blocker, [2] [3] noncompetitive NMDA receptor antagonist, [6] and monoamine oxidase B inhibitor. [7] [8]

As of 2020, it was in phase III clinical trials. [9] [5] [10] In 2010 it failed a phase II trial for lower back pain. [11] Encouraging Phase II results have been announced for neuropathic pain. [12]

See also

References

  1. ↑ Action A, ed. (22 July 2013). "Chapter 8: Therapies and Treatments". Pain: New Insights for the Healthcare Professional (2013 ed.). ScholarlyEditions. pp. 506–. ISBN   978-1-4816-6118-8.
  2. 1 2 3 Gilron I (21 June 2012). "Drug Discovery for Neuropathic Pain". In Simpson DM, McArthur JC, Dworkin RH (eds.). Neuropathic Pain: Mechanisms, Diagnosis and Treatment. Oxford University Press. pp. 40–. ISBN   978-0-19-539470-2.
  3. 1 2 3 Rodger IW, Lacouture PG (14 October 2010). "Overview: Novel Targets for New Analgesics". In Sinatra RS, Jahr JS, Watkins-Pitchford JM (eds.). The Essence of Analgesia and Analgesics. Cambridge University Press. pp. 436–. ISBN   978-1-139-49198-3.
  4. ↑ Termin A, Martinborough E, Wilson D (17 December 2008). "Recent Advances in Voltage-Gated Sodium Chanel Blockers: Therapeutic Potential as Drug Targets in the CNS". Annual Reports in Medicinal Chemistry. Academic Press. pp. 55–. ISBN   978-0-08-092187-7.
  5. 1 2 Liu Y, Qin N (26 January 2010). "Pharacological Modulation of Ion Channels for the Treatment of Chronic Pain". In Lu C, Li AP (eds.). Enzyme Inhibition in Drug Discovery and Development: The Good and the Bad. John Wiley & Sons. pp. 689–. ISBN   978-0-470-53894-4.
  6. ↑ Colombo E, Curatolo L, Caccia C, Salvati P, Faravelli L (2007). "344 Ralfinamide Acts Through Nmda Receptor Complex: A Central Role for Chronic Pain Treatment". European Journal of Pain. 11 (S1): S152 –S153. doi:10.1016/j.ejpain.2007.03.359. ISSN   1090-3801. S2CID   58186567.
  7. ↑ Di Stefano AF, Radicioni MM, Rusca A (May 2013). "Pressor response to oral tyramine and monoamine oxidase inhibition during treatment with ralfinamide (NW-1029)". Neurotoxicity Research. 23 (4): 315–326. doi:10.1007/s12640-012-9344-5. PMID   22872464. S2CID   207442119.
  8. ↑ Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G (14 April 2011). Rang & Dale's Pharmacology: with STUDENT CONSULT Online Access. Elsevier Health Sciences. pp. 2476–. ISBN   978-0-7020-4504-2.
  9. ↑ "Ralfinamide - Newron Pharmaceuticals". Adis Insight.
  10. ↑ Bowlby MR, Kaftan (9 December 2008). "Sodium Channel Blockers for the Treatment of Chronic Pain". In Gribkoff VK, Kaczmarek LK (eds.). Structure, Function and Modulation of Neuronal Voltage-Gated Ion Channels. John Wiley & Sons. pp. 377–. ISBN   978-0-470-42989-1.
  11. ↑ "Newron reports SERENA trial top-line results for ralfinamide". Bloomberg. 6 May 2010. Archived from the original on 24 September 2015.
  12. ↑ "Newron Announces Positive Results With Ralfinamide From Phase II Trial in Neuropathic Pain". PR Newswire. 26 October 2014. Archived from the original on 20 February 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.